ArchPoint Investors’s Travere Therapeutics TVTX Stock Holding History

ArchPoint Investors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-14,863	Closed	-$303K	–	121
2020 Q2	$303K	Hold	14,863	–	–	0.1%	78
2020 Q1	$217K	Hold	14,863	–	–	0.09%	82
2019 Q4	$211K	Hold	14,863	–	–	0.06%	94
2019 Q3	$172K	Buy	+14,863	New	+$246K	0.06%	83
2017 Q3	–	Sell	-2,500	Closed	-$48K	–	162
2017 Q2	$48K	Buy	+2,500	New	+$45.3K	0.02%	132

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ArchPoint Investors's TVTX Position: Q3 2020 in Review

ArchPoint Investors sold out of Travere Therapeutics (TVTX) in Q3 2020, closing a stake of 14,863 shares — an estimated $303K sold.

ArchPoint Investors first reported a position in TVTX in Q2 2017 and held it in 5 quarters. The position peaked at $303K in Q2 2020. 134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

ArchPoint Investors reported no remaining Travere Therapeutics position as of Q3 2020 after selling out during the quarter.
ArchPoint Investors sold 14,863 Travere Therapeutics shares in Q3 2020, an estimated $303K.
ArchPoint Investors first reported a position in Travere Therapeutics in Q2 2017 and held it in 5 quarters.
ArchPoint Investors's Travere Therapeutics position peaked at $303K in Q2 2020.
134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on ArchPoint Investors's 13F filing for Q3 2020, filed 13 Nov 2020.